Login    Join free Add to favorites    中文
home > news > Merck Expands Celonic鈥檚 Upstream Capabilities with Mobius® Single-use Bioreactors
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
Merck Expands Celonic鈥檚 Upstream Capabilities with Mobius® Single-use Bioreactors

hits:401     Date:09/14/17
  • Sizes range from 50-liter to 2,000-liter manufacturing scale
  • Industry-leading design offers flexibility, scalability and ease-of-use
 
Merck, a leading science and technology company, today announced that Celonic AG, a Swiss contract development and manufacturing organization (CDMO), is upgrading its manufacturing facility with five of Merck鈥檚 Mobius® single-use bioreactors.
 
Celonic, which produces biosimilars and also offers a cell line development platform, will add 50-, 200- and 2,000-liter bioreactors to its development and manufacturing facility in Basel, Switzerland. The upgrade will expand Celonic鈥檚 upstream capabilities, improving flexibility and scalability.
 
鈥淥ur extensive portfolio of single-use technologies allows us to support CDMO customers like Celonic as they adopt new technologies and expand their capabilities,鈥 said Andrew Bulpin, Head of the Process Solutions business unit, Life Science at Merck. 鈥淥ur new Mobius® single-use bioreactors will help Celonic streamline its processes and expand its capacity to better serve clients.鈥
 
鈥淔or our biotech customers, each step towards market authorization boosts the valuation of their assets, and that鈥檚 where Celonic鈥檚 breadth of services has been instrumental in creating tremendous value for our partners,鈥 said Konstantin Matentzoglu, CEO, Celonic. 鈥淢erck鈥檚 Mobius® single-use bioreactors offer a flexible, scalable system that addresses our needs and those of our clients. With the addition of the 2,000-liter bioreactor, we are moving a step closer to our objective of serving customers with commercial manufacturing needs.鈥
 
Single-use, disposable equipment and systems have increased in popularity in the biopharmaceutical industry, as they offer many advantages over conventional stainless steel systems, such as improved batch success rates, less cross- contamination risk, decreased water and waste water requirements, shortened project duration and reduced project costs.
 
At the same time, biopharmaceutical manufacturers are moving toward end-to-end solutions 鈥 from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply 鈥 as they seek to cut costs while increasing quality and efficiency.
 
Merck鈥檚 portfolio of 3- to 2,000-liter Mobius® single-use bioreactors delivers greater flexibility and continuity for scale-up, reducing the need for retraining operators. These are some of the multiple reasons that CDMOs such as Celonic have become early adopters of Merck鈥檚 technologies.
 
Merck is a premier supplier of process development and clinical-stage manufacturing solutions, materials and services needed for the production of biopharmaceutical drugs. The company is committed to delivering superior bioreactor technology to manufacturers, several of which are already collaborating with the company in that space in North America, Europe and Asia.
Related News>> more
advertisement

Copyright(C) 2006-2017 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙